Further, TIL abundance in ER+ tumors does not correlate strongly with prognosis, in contrast to TNBC and HER2+ cancers, where the abundance of TILs is associated with improved recurrence-free survival and better responses to neoadjuvant treatment and immune checkpoint inhibitors [21,46,47,48,49]. Here, ESR1 is linked to cancer.